查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球糖尿病视网膜病变市场
市场调查报告书
商品编码
1166532

2022-2029 年全球糖尿病视网膜病变市场

Global Diabetic Retinopathy Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

糖尿病会损害视网膜中的血管，称为糖尿病性视网膜病变 (DR)。 这种疾病有两种类型：非增殖性 DR 和增殖性或进行性 DR。 它是由于血糖水平的变化导致眼睛中感光组织异常生长引起的。 可能会出现视力模糊、视力不规则、色觉丧失，甚至视力下降。 治疗选择包括眼内类固醇注射、激光手术和玻璃体切除术。 也可通过荧光素血管造影、光学相干断层扫描等检查确诊。

市场动态

糖尿病患病率上升、糖尿病相关失明发生率上升以及眼科手术和诊断设备技术进步导致糖尿病视网膜病变将在预测期内推动市场。这是一个因素。

糖尿病视网膜病变诊断技术的进步有望推动市场增长。

Retina Labs 是糖尿病视网膜病变和其他眼病远程视网膜筛查的先驱。 iVision 远程眼科平台託管在云端，提供了一个综合解决方案，结合了先进的眼部成像、临床解释和报告工具以及电子转诊。 iVision 是一个远程眼科平台，专为希望缩小糖尿病眼病护理差距、改善结果和降低成本的医疗保健系统、初级保健提供者和医疗保健计划而设计。 因此，预计上述因素将在预测期内推动市场。

与糖尿病视网膜病变药物相关的副作用预计会阻碍市场增长。

Lucentis（雷珠单抗）的严重副作用包括眼内感染、白内障和视网膜脱离，这会导致视力模糊、光敏感和视力模糊。 此外，一些患者在註射前后眼压升高。 此外，还可能发生与血栓相关的致命问题，例如心脏病发作和中风。 致命事件很少见，死因是晚期糖尿病并发症患者的典型死因。 因此，预计上述因素将在预测期内阻碍市场。

COVID-19 影响分析

COVID-19 对糖尿病视网膜病变 (DR) 市场产生了负面影响。 根据国际防盲机构 (IAPB) 2021 年报告，无论地点或组织类型如何，每个人基本上都会受到影响。 至少 60% 的 DR 计划的预算被削减或完全放弃。 DR 服务的变化将对患有多种疾病的老年患者产生最大的影响。 地处偏远和社会经济地位低下对服务可及性的下降有很大影响。 受影响最大的还有各级医疗保健专业人员。 购买工具和药品的新障碍、不断变化的目标和相关报告带来的行政负担增加，以及为改善眼部健康的努力获得资金的难度增加，也对市场产生了影响。

此外，作为维持服务的策略，远程眼科和患者管理系统的引入、任务转移可能很复杂但对提供有弹性的服务和非面对面的沟通渠道很重要。增加对 因此，上述因素影响了市场，并有望在预测期内有所改善。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 糖尿病视网膜病变诊断技术的进步有望推动市场增长
    • 约束因素
      • 与糖尿病视网膜病变药物相关的副作用预计会阻碍市场增长。
    • 机会
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 供应链
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按适应症类型

  • 非增殖性糖尿病视网膜病变
  • 增生性糖尿病视网膜病变

第 8 章按药物类型分类

  • 抗血管内皮生长因子 (VEGF) 製剂
    • 雷珠单抗（Lucentis）
    • 阿柏西普玻璃体内註射 (Eylea)
    • 其他
  • 类固醇眼内註射
  • 激光手术
  • 玻璃体手术
  • 其他

第 9 章最终用户

  • 最终用户
    • 医院
    • 眼科诊所
    • 门诊手术中心
    • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第12章公司简介

  • Abbott Laboratories
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Alimera Science
  • Allergan plc
  • Ampio Pharmaceuticals.
  • Bayer AG
  • Hoffmann-La Roche
  • Novartis International AG
  • Glycadia Pharmaceuticals
  • Regeneron Pharmaceuticals Inc.
  • Valeant Pharmaceutical

第13章 全球糖尿病性视网膜病变市场 - DataM

简介目录
Product Code: DMPH29

Market Overview

Diabetes mellitus harms the retina's blood vessels, referred to as diabetic retinopathy (DR). There are two different types of this condition: non-proliferative DR and proliferative or advanced DR. It is brought on by changes in blood glucose levels, which cause the light-sensitive tissues in the eye to grow abnormally. Dark spots or floating strings can be seen in the field of vision, along with blurred or erratic vision, reduced color perception, and even loss of vision. Treatment options include intraocular steroid injection, laser surgery, and vitrectomy. It can be diagnosed using tests like fluorescein angiography and optical coherence tomography.

Market Dynamics

The increasing prevalence of diabetes, rising incidence of diabetes-related blindness, and technological advancements in ophthalmic surgical and diagnostic instruments will enable diabetic retinopathy are the factors to drive the market in the forecast period.

Technological advancement in diagnosing diabetic retinopathy is expected to drive market growth.

Retina Labs has pioneered teleretinal screening for diabetic retinopathy and other ocular disorders. The iVision teleophthalmology platform, hosted in the cloud, provides an integrated solution that combines advanced ocular imaging, clinical interpretation and reporting tools, and electronic referrals. The company's solutions enable healthcare providers to improve access to high-quality eye care while streamlining processes for managing chronic eye diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration, and retinopathy of prematurity. iVision is a teleophthalmology platform designed for health systems, primary care providers, and health plans looking to close care gaps in diabetic eye disease, improve outcomes, and lower costs. Thus, from the above factors, the market is expected to drive in the forecast period.

Side effects associated with the drugs treating diabetic retinopathy are expected to hamper the market growth.

The serious side effects of the LUCENTIS (ranibizumab) drug include infections inside the eye, cataracts, and detached retinas, which can cause blurry vision, light sensitivity, and cloudy vision. Some patients have experienced increased eye pressure before and after injection-moreover, sometimes fatal, blood clot-related problems, such as heart attacks or strokes. Although there were only a few fatal events, the causes of death were typical of patients with advanced diabetic complications. Thus, from the above factors, the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

COVID-19 impacted the diabetic retinopathy(DR) market negatively. According to the International Agency for the Prevention of Blindness (IAPB) report 2021, everybody was essentially affected, regardless of their location or type of organization. At least 60% of DR initiatives had their budgets cut or were completely abandoned. Changes in DR services have the biggest effects on elderly patients with multiple diseases. Reduced access to services is significantly impacted by remoteness and low socioeconomic status. The most impacted individuals are also all levels of healthcare professionals. The market is also affected by new obstacles related to the purchase of tools and medications, a rise in the administrative burden brought on by shifting targets and associated reporting, and growing difficulty in securing funding for initiatives to improve eye health.

Furthermore, the introduction of teleophthalmology and patient flow management were common strategies to retain services, as was task shifting, which was complex but potentially important in providing resilient services, and increased reliance on non-face-to-face communication channels. Thus, from the above factors, the market got affected and is expected to improve in the forecast period.

Segment Analysis

Laser Surgery segment is expected to hold the largest market share in diabetic retinopathy

The laser surgery segment accounted for the largest market share in 2021. Laser treatment usually works well to prevent vision loss before the retina has been severely damaged. Macular edema may benefit as well. This can reduce the swelling of the retina. Laser surgery can also helps in shrinking blood vessels and prevent them from growing again.

Moreover, severe proliferative retinopathy is treated using a more aggressive laser therapy known as scattering (pan-retinal) photocoagulation. It allows doctors to control the spread of new blood vessels across the retina's back. Therefore, there is increased demand for laser surgery for treating diabetic retinopathy. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global diabetic retinopathy market

North America region accounted for the largest market share in 2021. The increasing prevalence of diabetes, the rising geriatric population, increasing FDA approvals in the region and increasing awareness about diabetic retinopathy among people are the factors to drive the market in the forecast period. For instance, according to the IDF Diabetes Atlas 10th Edition, an estimated 51 million adults aged 20-29 were living with diabetes in the IDF NAC region in 2021, representing a regional prevalence of 14.6%. The region has the second-highest number of children and adolescents with type 1 diabetes (193,000).

Additionally, on June 29, 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. FDA has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application (sBLA) for every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR). The target action date for the FDA decision is on February 28, 2023. Thus, from the above-mentioned factors, the North America region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the diabetic retinopathy market are Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals, Bayer AG, Hoffmann-La Roche, Novartis International AG, Glycadia Pharmaceuticals, Regeneron Pharmaceuticals Inc and Valeant Pharmaceutical.

Regeneron Pharmaceuticals, Inc.:

Overview:

Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown in 1988. The company engages in the discovery, invention, development, manufacture, and commercialization of medicines. The biopharmaceutical company develops and manufactures medicines designed to treat a range of illnesses, including asthma, chronic pain, cancer, and infectious diseases. Product portfolio includes the following brands such as EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Product Portfolio:

EYLEA (AFLIBERCEPT) INJECTION: EYLEA is the only vascular endothelial growth factor (VEGF) inhibitor approved with two dosing options for diabetic retinopathy (DR). EYLEA helps in treating all stages of diabetic retinopathy (DR), thereby reducing the risk of blindness.

The global diabetic retinopathy market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement in diagnosing diabetic retinopathy is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs treating diabetic retinopathy are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Indication Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 7.1.2. Market Attractiveness Index, By Indication Type
  • 7.2. Non-Proliferative Diabetic Retinopathy*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Proliferative Diabetic Retinopathy

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Anti-Vascular Endothelial Growth Factor (VEGF)*
      • 8.2.1.1. Ranibizumab (Lucentis)*
      • 8.2.1.2. Introduction
      • 8.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 8.2.1.4. Aflibercept intravitreal (Eylea)
      • 8.2.1.5. Others
  • 8.3. Intraocular Steroid Injection
  • 8.4. Laser Surgery
  • 8.5. Vitrectomy
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. End user*
      • 9.2.1.1. Hospitals
      • 9.2.1.2. Introduction
      • 9.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 9.2.1.4. Ophthalmic Clinics
      • 9.2.1.5. Ambulatory Surgical Center
      • 9.2.1.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Alimera Science
  • 12.3. Allergan plc
  • 12.4. Ampio Pharmaceuticals.
  • 12.5. Bayer AG
  • 12.6. Hoffmann-La Roche
  • 12.7. Novartis International AG
  • 12.8. Glycadia Pharmaceuticals
  • 12.9. Regeneron Pharmaceuticals Inc.
  • 12.10. Valeant Pharmaceutical

LIST NOT EXHAUSTIVE

13. Global Diabetic Retinopathy Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us